TFDP1 and hepatocellular carcinoma: In an E2F1-driven transgenic HCC mouse model engineered by Conner et al. in which the interaction with TFDP1 was validated [23], we identified strikingly higher stathmin immunoreactivity not only in the full-blown tumors (Additional file 1: Figure S5a, left column) but also in the precursor lesions (Additional file 1: Figure S5a, right column) compared to the adjacent liver tissue.